Skip to content

Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway

Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway: A Potential New Therapeutical Intervention for Postoperative Ileus

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02425774
Enrollment
31
Registered
2015-04-24
Start date
2014-07-01
Completion date
2016-02-27
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Ileus

Keywords

Prucalopride, Vagus Nerve Stimulation, Postoperative Ileus

Brief summary

Hypothesis: Prucalopride can mimic electrical stimulation of the abdominal vagus nerve and has an anti-inflammatory effect. Aims: In the present pilot study, the investigators want to evaluate the anti-inflammatory effect of prucalopride. The following aims are formulated: 1. to show that prucalopride has a similar inflammatory effect as abdominal vagus nerve stimulation (VNS) 2. to evaluate whether prucalopride leads to accelerated post-operative recovery

Interventions

PROCEDURESham stimulation
DRUGPrucalopride
DRUGPlacebo

Sponsors

KU Leuven
Lead SponsorOTHER
Universitaire Ziekenhuizen KU Leuven
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients undergoing partial or full resection of the pancreas due to a benign or malignant tumor

Exclusion criteria

* adjuvant radiotherapy * evident intra-abdominal inflammation (diagnosed by imaging and/or laboratory results, including an abscess or cholecystitis) * chronic pancreatitis * pancreatic polypeptide producing endocrine tumor * American Society of Anesthesiologists physical-health status classification (ASA-PS)\>3 * Poorly regulated diabetes (\>200 mg/dl (=11 mmol/l))

Design outcomes

Primary

MeasureTime frame
Levels of pro-inflammatory cytokines in intestinal tissue, serum, peritoneal lavage and supernatant of stimulated whole bloodFrom the date of surgery until the date of lab analysis (up to 6 months)

Secondary

MeasureTime frame
Time to first flatusFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Time to tolerance of oral food intakeFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Time to tolerance of oral food intake AND first defecationFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Time to first defecationFrom the date of surgery until the date of discharge from the hospital (on average 14 days)
Gastrointestinal symptoms (nausea, pain, vomiting, bloating)From the date of surgery until the date of discharge from the hospital (on average 14 days)
Time to discharge from the hospitalFrom the date of surgery until the date of discharge from the hospital (on average 14 days)

Countries

Belgium

Contacts

PRINCIPAL_INVESTIGATORGuy Boeckxstaens, M.D.

Catholic University Leuven

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026